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Conventional algorithms for diagnosis and treatment of gas-
trointestinal bleeding (GIB) in patients with nonpulsatile ven-
tricular assist devices (VADs) may take days to perform while 
patients require transfusions. We developed a new algorithm 
based on deep overtube-assisted enteroscopy (DOAE) to facili-
tate a rapid diagnosis and treatment. From 2004 to 2012, 84 
patients who underwent VAD placement in our institution, 
were evaluated for episodes of GIB. Our new algorithm for 
the management of GIB using DOAE was evaluated by dividing 
the episodes into three groups: group A (traditional manage-
ment without enteroscopy), group B (traditional management 
with enteroscopy performed >24 hours after presentation), and 
group C (new management algorithm with enteroscopy per-
formed <24 hours after presentation). Gastrointestinal bleed-
ing was observed in 14 (17%) of our study patients for a total of 
45 individual episodes of which 28 met our criteria for subanal-
ysis. Forty-one (84%) lesions were confined to the upper gas-
trointestinal tract with more than 91% of these lesions being 
arteriovenous malformations. Average number of transfusions 
in groups A, B, and C were 4.1, 6.3, and 1.3, respectively 
(p = 0.001). The number of days to treatment was significantly 
shorter in group C than group B (0.4 vs. 5.3 days, p = 0.0002). 
Our new algorithm for the management of GIB using DOAE 
targets the most common locations of bleeding found in this 
patient population. When performed early, DOAE has the 
potential to decrease the need for transfusions and allow for an 
early diagnosis of GIB in VAD recipients. ASAIO Journal 2013; 
59:384–389.
Key Words: gastrointestinal bleeding, ventricular assist 
device, mechanical circulatory support, enteroscopy
Ventricular assist devices (VADs) are used to treat advanced 
heart failure either as a bridge to transplant or as destination 
therapy.1 The majority of VADs currently implanted are con-
tinuous flow VADs (CFVADs) which create nonpulsatile blood 
flow. These CFVADs are smaller and have increased longev-
ity than the previous pulsatile VAD.2 Gastrointestinal bleeding 
(GIB) has a reported incidence of 18%–40% in patients with 
a VAD and is known to be much more common in patients 
with the CFVAD.2,3 Treatment of each episode of GIB requires 
the discontinuation of anticoagulation, which carries a risk for 
developing a thrombus in the pump and possible subsequent 
embolization.4 While a diagnosis is pursued, patients receive 
blood transfusions which have been known to increase the risk 
of infection and development of additional antibodies.5,6 The 
traditional GIB algorithms for diagnosis and treatment can vary 
widely from center to center and can take days to complete. 
The current management of GIB in these VAD patients follows 
the same algorithms used for the general population and does 
not take into consideration the specialized needs of patients 
who are on mechanical circulatory support. Patients with a 
VAD who develop GIB need a faster diagnosis and treatment 
so that anticoagulation can be resumed and transfusions can 
be minimized. Thus, we reviewed our VAD patients who devel-
oped postoperative GIB to identify bleeding characteristics and 
the management performed. We propose a new algorithm that 
acts to shorten the time to diagnosis and treatment.
Methods
Patients
After obtaining approval from the hospital internal review 
board, a retrospective chart review was performed on all 
patients receiving a VAD at our institution from 2004 to 
2012. Demographic data were generated from The Society 
of Thoracic Surgeons (STS) national database. Each chart was 
reviewed looking for episodes of GIB from the date of VAD 
implant through the duration of follow-up. A total of 84 patients 
were identified of which 25 had a pulsatile VAD and 59 had a 
CFVAD. Patient demographics were described in Table 1.
Left Ventricular Assist Device Placement and Management
Two types of VADs were implanted; pulsatile VAD (Nova-
cor and Abiomed AB5000) and CFVAD (HeartMate II and 
Jarvik) during the study period. The Novacor (Novacor Corp., 
Oakland, CA), HeartMate II (Thoratec, Pleasanton, CA), and 
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Abiomed AB5000 (Abiomed, Danvers, MA) were placed via 
standard sternotomy between the left ventricular apex and 
the ascending aorta, and the Jarvik 2000 (Jarvik Heart Inc., 
New York, NY) was placed via left thoracotomy between the 
left ventricular apex and the mid-descending aorta. The VAD 
pocket was created anterior to the diaphragm, and no VAD was 
placed in the abdominal cavity. Device selection was individu-
alized to each patient and the indications were as a bridge to 
transplant for 54 (64%) patients and as destination therapy for 
30 (36%). Postoperatively, all patients, regardless if on pulsatile 
(Novacor and Abiomed) or CFVAD (HeartMate II and Jarvik), 
were started on an antiplatelet drug on postoperative day 1 
begun on a heparin bridge to Coumadin with a goal interna-
tional normalized ratio (INr) of 1.8–2.0 on postoperative day 
2. If patients had a history of atrial fibrillation, the target INr 
was increased to 2.5. No patients in this study had a history of 
documented GIB before VAD placement. All patients received 
a proton-pump inhibitor after VAD insertion that was contin-
ued unless a contraindication existed.
Definition of Gastrointestinal Bleeding
An episode of GIB was defined as heme-positive stool or 
hematemesis and a decrease in hemoglobin >1 g/dl. The reso-
lution of GIB was defined as the stabilization of hemoglobin 
for a minimum of 24 hours. Transfusion triggers were contin-
ued bleeding, hemoglobin level below 7 g/dl, or hemodynamic 
instability. Gastrointestinal bleeding data acquisition was com-
pleted by January 2012.
Definition of Upper and Lower Gastrointestinal Tract
For the purpose of diagnosing GIB, traditionally the gas-
trointestinal tract is divided into upper (esophagus, stomach, 
and duodenum) and lower (jejunum, ileum, colon, and rec-
tum) regions. With the development of new technology which 
allows the passage of an enteroscope from the mouth through 
the duodenum into the distal small bowel, the upper gastro-
intestinal tract was redefined as esophagus, stomach, duo-
denum, jejunum, and ileum; or all areas accessible by the 
enteroscope.7 The lower gastrointestinal tract was defined as 
distal ileum, colon, rectum, and anus.
Traditional Gastrointestinal Bleeding Work-up
Patients presenting with GIB had all anticoagulation 
stopped and gastroenterology was consulted for the appropri-
ate workup. A traditional diagnostic algorithm is displayed in 
Figure 1. Variations of this algorithm exist and the performed 
tests dictated by the gastroenterology service.
New Technology and Algorithm
Deep overtube-assisted enteroscopy (DOAE) is a new and 
emerging technology that uses a standard enteroscope with an 
overtube to view the esophagus and stomach first, then the 
bowel of the duodenum, jejunum, and ileum. There are three 
different instruments used to perform this intervention: single-
balloon (Olympus Optical, Tokyo, Japan), double-balloon 
(Fujinon Inc., Saitama, Japan), and spirus enteroscopy (Spirus 
Medical Inc., Stoughton, MA). The new technologies allow the 
gastroenterologist to pleat the small bowel over the enteroscope 
and overtube allowing them to visualize the small bowel distal 
to the ligament of Treitz. Although three different instruments 
exist to perform DOAE, preference for which instruments are 
used lies with the individual gastroenterologist. Using this new 
technology of enteroscopy, a new algorithm was created for 
diagnosis and treatment of GIB (Figure 2).
Subgroup Analysis
In the 14 patients who experienced GIB, 45 individual 
episodes were identified. To evaluate the efficacy of early use 
of the DOAE in the work-up of GIB in VAD patients, a subgroup 
Table 1.  Demographics
Variable
Without Gastrointestinal 
Bleeding
n = 70
With Gastrointestinal 
Bleeding
n = 14 p Value
Age, mean ± SD 53 ± 13 58 ± 10 0.164
Male 51 (73%) 11 (79%) 0.368
Device
 Pulsatile device 25 (36%) 0 (0%) 0.0079
 Nonpulsatile device 45 (64%) 14 (100%) 0.0076
Race
 Caucasian 44 (63%) 7 (50%) 0.037
 African American 16 (23%) 7 (50%) 0.131
 Other 10 (14%) 0 (0%) 0.702
Preoperative risk factors
 Smoker 12 (17%) 3 (21%) 0.702
 Diabetes 27 (39%) 6 (43%) 0.764
 Hyperlipidemia 40 (57%) 9 (64%) 0.621
 Hypertension 52 (74%) 9 (64%) 0.444
 Cardiogenic shock 26 (37%) 3 (21%) 0.259
Postoperative discharge medications for 
(for CFVAD only)
n = 45 n = 14
 Anticoagulation 45 (100%) 14 (100%) 1.000
 Antiplatelet 45 (100%) 14 (100%) 1.000
CFVAD, continuous flow ventricular assist device.
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analyses was performed. Ten episodes of obvious colonic 
bleeding, which were not eligible for DOAE, were treated 
with colonoscopy and were not included in this subgroup 
analysis. Five episodes of gastric bleeding were not included 
because a standard DOAE includes an upper endoscopy; 
thus these lesions would have been found and treated with 
DOAE on initial pass. Two episodes were excluded because 
of hemodynamic instability that prohibited the patient from 
undergoing endoscopy. A total of 28 episodes in 12 patients 
were eligible for our subgroup analysis, which were divided 
into three groups based on the GIB work-up performed. Group 
A (traditional management without DOAE) consisted of patients 
with GIB who did not undergo DOAE at any point during 
their hospital stay despite multiple other imaging modalities 
(bleeding scans, upper endoscopy, colonoscopy, etc.) being 
performed. The bleeding episode, in this subgroup, resolved 
without a clear source being identified. Group B (traditional 
management with DOAE performed >24 hours) consisted 
of patients who underwent multiple imaging modalities 
that ultimately resulted in enteroscopy being performed 24 
hours or more after presentation to the hospital. Group C 
(new management algorithm with enteroscopy <24 hours) 
consists of individuals who received a DOAE within 24 hours 
of presentation to the hospital as the initial test performed. 
Outcome measures were the number of packed red blood cells 
transfused, the number of days from presentation to treatment, 
and the number of diagnostic/treatment procedures performed.
Statistics
Data were expressed as a mean with standard deviation 
or number and corresponding percentage as appropriate. 
Continuous variables were compared using a two-tailed Stu-
dent’s t-test, and categorical variables were compared using 
Figure 1. Traditional gastrointestinal bleeding management algorithm. DRE, digital rectal examination; EGD, esophagogastroduodenos-
copy; GIB, gastrointestinal bleeding; NG, nasogastric lavage; RBC, red blood cell scan.
Figure 2. New algorithm for diagnosis and treatment of gastrointestinal bleeding in patients with a ventricular assist device. DOAE, deep 
overtube-assisted enteroscopy; GIB, gastrointestinal bleeding; RBC, red blood cell scan.
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chi-square test or Fisher’s exact test. Comparisons of the afore-
mentioned subgroups were performed using one-way ANOVA. 
p < 0.05 was considered significant.
results
Among the 84 patients who received a VAD during the study 
period, 14 (17%) developed at least one episode of GIB dur-
ing mean follow-up period of 33.6 ± 19.8 months. Of these 
patients with GIB, all 14 (100%) had a CFVAD; none were 
pulsatile. Five (35%) patients developed the sentinel bleed 
within 30 days from date of VAD implant, whereas eight (57%) 
developed the first episode of GIB from 31 days to 1 year. There 
was one outlier at 612 days who had one isolated incident. 
The average time from implant to the first episode of GIB was 
65 ± 62 days excluding the outlier mentioned earlier. Of the 14 
patients, 10 patients (72%) developed a second bleed, seven 
(50%) developed a third bleed, five (36%) a fourth, and three 
(21%) a fifth. All 13 patients who developed a sentinel bleed 
within 1 year of VAD implant had each subsequent bleeding 
episode within 1 year of the initial event.
During the study period, a total 45 individual episodes of 
GIB occurred in 14 patients. The mean INr on presentation of 
a VAD patient with an episode of GIB was 1.85 ± 1.32, whereas 
64% of the episodes had an INr <1.5. A variety of tests were 
used to identify the location of the GIB. In the 45 episodes that 
met the criteria for the definition of GIB, 49 individual sites 
were identified for analysis with four episodes having multiple 
locations of bleeding. Among the 49 lesions of GIB, 45 (92%) 
were from arteriovenous malformations (AVM), one (2%) was 
from a bleeding Dieulafoy’s lesion, one (2%) was a bleeding 
polyp in the duodenum, and two (4%) were diverticular bleeds. 
Forty-one (84%) were from upper gastrointestinal tract and 
eight (18%) from lower gastrointestinal tract as defined previ-
ously. The detail of the GIB location and type is shown in Table 
2. Most of the bleeding sites, 41 (84%), were within the reach of 
DOAE for diagnosis and treatment during the same procedure.
Details of the subgroup analyses can be seen in Table 3. Enter-
oscopy was performed in 13 (46%) of the 28 episodes and was 
able to detect 13 individual GIB sites. Treatment was performed 
using either argon plasma coagulation or through injection of a 
sclerosing agent. Patients with GIB who underwent enteroscopy 
as the initial test and therapy during the first 24 hours of pre-
sentation to the hospital (group C) achieved significantly faster 
resolution of GIB than patients who had delayed enteroscopy 
after other imaging modalities had been performed (group B). 
In comparing the number of transfusions, patients in group C 
received significantly fewer units of blood when compared with 
groups A and B, 1.3 vs. 4.1 and 6.3 (p = 0.001), respectively. 
The number of diagnostic tests performed on patients in group 
C averaged 1.1 per episode, which was significantly fewer than 
2.4 and 3.5 for groups A and B (p = 0.005).
Discussion
The Interagency registry for Mechanically Assisted Cir-
culatory Support (INTErMACS) reports have shown a steady 
increase in the number of VAD implants as a bridge to trans-
plant or as destination therapy during the last 5 years. This is, 
in part, because of the VAD’s smaller size, ease of implant, and 
decrease in complication rates.3
recent studies of GIB in VAD patients showed that 18%–
40% develop GIB while receiving VAD therapy and have also 
shown a difference between the pulsatile VAD and CFVAD.8–10 
Crow et al.10 found that patients with CFVAD had GIB rates 10 
times as much as patients with pulsatile VADs. The shift from 
the early VADs, which used a pulsatile system to mimic nor-
mal cardiac output, to the modern CFVAD being used today 
has come with an increased propensity for patients to develop 
GIB.10 With the increasing number of implanted CFVADs, 
many have postulated the reasons for the increased propen-
sity to develop GIB in this population. In as early as 1958, 
Heyde11 found increased rates of GIB in patients with aortic 
stenosis. Modern day CFVADs produce a continuous flow, 
which is similar to what is seen in patients with severe aortic 
stenosis. The severely stenotic valve creates high shear stress 
across the aortic leaflets leading to denaturing of von Will-
ebrand factor (vWF) multimers, which promotes their destruc-
tion.10,12 With the proteolytic cleavage of this factor, patients 
develop acquired vWF disease that increases their propensity 
to bleed.13In addition, CFVADs are known to alter the vis-
ceral circulation leading to an increased intraluminal pressure 
which leads to dilation of mucosal veins and AVM develop-
ment.14 CFVADs also decrease gastrointestinal mucosal perfu-
sion, which may lead to mucosal ischemia and an increased 
propensity to develop bleeding at those sites.15 The cause of 
GIB is likely a combination of all of these factors. Interestingly, 
after removal of the VAD with either cardiac recovery or a 
transplant, the episodes of GIB abate.9
Each individual, when presenting with an episode of GIB, may 
require readmission, reversal or cessation of anticoagulation, 
multiple imaging modalities to attempt to identify and treat 
the source of bleeding, and last, multiple transfusions. Each 
discontinuation of anticoagulation places the patient at risk 
for device thrombosis and potential embolization; thus a 
speedy diagnosis and therapy are important.5 Episodes of 
GIB may not be simply controlled with lowering INr or 
stopping the antiplatelet agent. Our study found that 64% 
of our patients had an INr <1.5 on presentation suggesting 
that the INr alone was not responsible for the bleeding. Each 
diagnostic test requires time to complete and most require a 
bowel preparation that can affect the patient’s hemodynamics 
caused by dehydration. During the work-up phase, patients 
receive multiple transfusions that increase the risk of antibody 
development and can affect the ability of the patient to receive 
a future heart transplant.16 Most importantly, despite recent 
improvements in technology, the traditional algorithms we use 
to treat GIB were primarily designed for the general population 
and are not specific for VAD patients.
Table 2.  Location and Description of the Lesions Identified in 
the 45 Episodes (49 Lesions)*
Location
Number of 
Lesions Type of Lesion
Stomach 7 (14%) 7 AVM
Duodenum 20 (41%) 18 AVM, 1 Dieulafoy’s lesion, 1 polyp
Jejunum 13 (26%) 13 AVM
Ileum 1 (2%) 1 AVM
Colon 8 (16%) 6 AVM, 2 diverticulosis
*Some individuals had more than one bleeding lesion.
AVM, arteriovenous malformation.
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Technology has seen many improvements during the last 
decade, especially when examining the small bowel. Our 
results showed that the majority of lesions were seen in the 
small intestine with the duodenum, jejunum, and ileum 
accounting for 69% of all lesions encountered. Aggarwal et al.3 
showed that 57% of the patients they identified had the upper 
gastrointestinal tract including the proximal small bowel as the 
source of bleeding with 44% of them experiencing recurrent 
bleeding. In their cohort of patients, Elmunzer et al.17 discov-
ered that almost all subjects sustained hemorrhage from an 
upper gastrointestinal source which confirms our belief that 
the initial focus for a source needs to be the proximal gastro-
intestinal tract.
Bleeding from the small intestine used to be difficult to diag-
nose because of the lack of adequate instruments to visualize 
the lumen with surgery being the only option.14 In 2001, the 
emergence of capsule endoscopy allowed us to visualize the 
lumen of the small intestine.18 The capsule, once swallowed, 
takes multiple images of the small bowel to identify the source 
of bleeding as it traverses through the intestine.19 Because cap-
sule endoscopy is purely diagnostic, once a lesion is identified, 
patients require another procedure for treatment.20
In early 2001, a new technology called DOAE was created 
and was being used to treat GIB. Yamamoto et al.21 reported on 
the first use of a double-balloon enteroscope which allowed 
access to the duodenum, jejunum, and ileum not only for visu-
alization but also for concurrent treatment. The technology 
uses an enteroscope backloaded with an overtube to visualize 
the small intestine.19 The overtube and endoscope each have 
a balloon on the end; once the scope enters the small bowel, 
the balloons are sequentially inflated and deflated while the 
overtube is retracted and the enteroscope is advanced.19 This 
congruent sequence “pleats” the small bowel over the entero-
scope allowing it to advance further in the small bowel. Since 
2001, single-balloon enteroscopy and spirus enteroscopy have 
also emerged. Single-balloon enteroscopy uses an overtube 
like in double-balloon enteroscopy, whereas spirus enteros-
copy uses a helical overtube which is also backloaded over the 
enteroscope. The overtube has raised ridges wrapped circum-
ferentially, similar to a cork-screw, and when rotated, will pleat 
the bowel in a circular manner over the overtube allowing for 
the visualization of the small bowel.22 Diagnostic yields, when 
compared between single-balloon enteroscopy and spiral 
enteroscopy, are not statistically significant,23 and the rate of 
complications remains low. Complications of these technolo-
gies, when used exclusively for diagnosis, are less than 1% 
but may approach 4% when used for treatment.24 Elmunzer et 
al.17 point out that enteroscopy is safe and essential to evaluate 
the gastrointestinal tract and paramount to treatment of GIB 
in patients with a VAD.17 Each of these new technologies has 
been developed during the last decade and offer VAD patients 
with GIB a quick diagnosis and therapy of the most commonly 
found lesions in the small bowel, thus eliminating additional 
tests and reducing the time to treatment.
Looking at the characteristics of the patients in our study, 
patients with a pulsatile VAD did not experience a single epi-
sode thus, all of our GIB was observed in CFVAD. The majority 
of patients (92%) presented with a sentinel bleed within the 
first year of implant. The most common location of GIB was 
in the duodenum and jejunum (67%), whereas the colon only 
accounted for 16%. With most of our lesions being confined to 
the proximal small bowel (stomach, duodenum, and jejunum), 
enteroscopy was successful in treating these lesions on the first 
pass. Approximately one third of the GIB lesions were con-
fined to the jejunum and ileum and would not be diagnosed 
without capsule endoscopy or DOAE and be missed. Patients 
who received enteroscopy on initial presentation, received 
fewer units of packed red blood cells, fewer diagnostic tests, 
and had a decreased time to diagnosis and treatment when 
compared with patients who received DOAE after other tests 
had been done which failed to localize bleeding or in patients 
who did not have DOAE done at all. The episodes where the 
new technology of DOAE was used did not experience any 
complications or adverse events. This discovery led us to create 
a new GIB work-up algorithm (Figure 2) designed specifically 
for the VAD patient focusing on performing DOAE early in a 
patient’s hospital course.
The focus of our new algorithm is prompt assessment of 
the most common location of bleeding in the gastrointestinal 
tract. Lower GIB can be screened at presentation by digital 
rectal examination and a careful medical history to identify 
conditions which can make the patient more prone to bleed 
from the colon. If lower GIB is suspected, colonoscopy should 
be scheduled. Otherwise, all patients without a history of lower 
GIB should be scheduled for a DOAE based on the frequency 
and most common locations of the offending lesions. Our 
data suggest a potential advantage of incorporating our new 
algorithm for the management of GIB in VAD patients.
Although our results proved to have statistical significance, 
our study has limitations. Our study was performed at a single 
center where the number of the patients is relatively small and 
a multicenter study would be ideal. A standardization of the 
management of GIB is essential; however, it is difficult because 
most centers are using an individually constructed manage-
ment plan. In addition, the definition of GIB needs to be 
standardized; studies presented in the literature use multiple 
Table 3.  Subgroup Analysis of Gastrointestinal Bleeding
Group A: Traditional  
Without Enteroscopy
Group B: Traditional 
With Enteroscopy
Group C: New 
Management Algorithm p Value
Episodes 15 6 7
Enteroscopy Never Late Early
Average transfused packed red cells 4.1 6.3 1.3 0.001
Days to treatment n/a 5.3 0.4 0.0002
Average number of tests performed 2.4 3.5 1.1 0.005
Group A: episodes where no diagnosis was ever made and patients did not undergo an enteroscopy. Group B: episodes that underwent 
multiple diagnostic/therapeutic modalities with enteroscopy being performed >24 hours after the admission for treatment. Group C: episodes 
where enteroscopy was performed within 24 hours of presentation.
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definitions and make comparison of significant events very dif-
ficult between centers. randomized comparison between the 
traditional GIB algorithm and our new algorithm will be dif-
ficult at our institution because we are no longer following the 
traditional algorithm.
Conclusion
With the population of VAD patients growing each year, 
physicians will be increasingly forced to deal with complica-
tions of this therapy. We identified that most GIB lesions in 
patients with CFVAD are AVMs and are located either in the 
stomach, duodenum, jejunum, or ileum. Noting the location 
of these lesions, only DOAE allows for the visualization and 
treatment of these lesions to occur during the same procedure 
without having to take the patient to surgery. The prompt initia-
tion of enteroscopy, either double-balloon, single-balloon, or 
spirus, can allow for rapid identification and treatment of these 
lesions, thereby limiting the number of tests performed and 
decreasing the number of transfusions that the patients receive.
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